These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

116 related items for PubMed ID: 766071

  • 1.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 2.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 3. Therapy of sickle cell disease: an approach with sodium cyanate.
    Peterson CM, Cerami A.
    Semin Hematol; 1974 Oct; 11(4):569-76. PubMed ID: 4213637
    [No Abstract] [Full Text] [Related]

  • 4.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 5. The pharmacology of cyanate with a summary of its initial usage in sickle cell disease.
    Gillette PN, Lu YS, Peterson CM.
    Prog Hematol; 1973 Oct; 8():181-90. PubMed ID: 4788375
    [No Abstract] [Full Text] [Related]

  • 6.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 7. Cyanate as an inhibitor of red-cell sickling.
    Cerami A.
    N Engl J Med; 1972 Oct 19; 287(16):807-12. PubMed ID: 4560520
    [No Abstract] [Full Text] [Related]

  • 8.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 9.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 10. Gas chromatographic determination of the carbamylation of hemoglobin S by cyanate.
    Manning JM, Lee CK, Cerami A, Gillette PN.
    J Lab Clin Med; 1973 Jun 19; 81(6):941-5. PubMed ID: 4710373
    [No Abstract] [Full Text] [Related]

  • 11. Preliminary studies of continuous extracorporeal carbamylation in the treatment of sickle cell anemia.
    Balcerzak SP, Grever MR, Sing DE, Bishop JN, Segal ML.
    J Lab Clin Med; 1982 Sep 19; 100(3):345-55. PubMed ID: 7108349
    [Abstract] [Full Text] [Related]

  • 12.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 13. Cyanate effect on sickling.
    Charache S, Milner PF.
    N Engl J Med; 1972 Dec 28; 287(26):1357-8. PubMed ID: 4635027
    [No Abstract] [Full Text] [Related]

  • 14.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 15. Bioavailability of sodium cyanate in patients with sickle cell disease and the lack of inhibition in vitro of globin synthesis at in vivo concentrations of cyanate.
    Nigen AM, Manning JM, Peterson CM, White JM.
    J Pharmacol Exp Ther; 1975 Nov 28; 195(2):333-9. PubMed ID: 1185602
    [Abstract] [Full Text] [Related]

  • 16. Toxic-therapeutic ratio of sodium cyanate.
    Charache S, Duffy TP, Jander N, Scott JC, Bedine M, Morrell R.
    Arch Intern Med; 1975 Aug 28; 135(8):1043-7. PubMed ID: 1156065
    [Abstract] [Full Text] [Related]

  • 17. Effect of cyanate on red blood cell sickling.
    Cerami A, Manning JM, Gillette PN, De Furia F, Miller D, Graziano JH, Peterson CM.
    Fed Proc; 1973 Jun 28; 32(6):1668-72. PubMed ID: 4268029
    [No Abstract] [Full Text] [Related]

  • 18.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 19. Effect of cyanate on sickling.
    May A, Bellingham AJ, Huehns ER, Beaven GH.
    Lancet; 1972 Mar 25; 1(7752):658-61. PubMed ID: 4125163
    [No Abstract] [Full Text] [Related]

  • 20. An extracorporeal system that modifies hemoglobin in patients with sickle cell anemia.
    Babb AL, Scribner BH, Uvelli DA, Fry DL, Agodoa LC.
    Artif Organs; 1979 Feb 25; 3(1):62-72. PubMed ID: 435126
    [No Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 6.